46 related articles for article (PubMed ID: 1932377)
1. Interleukin-1 and tumor necrosis factor-alpha in plasma of patients with acute ischemic heart disease who undergo thrombolytic therapy: a randomized, placebo-controlled study.
Munkvad S; Gram J; Jespersen J
Lymphokine Cytokine Res; 1991 Aug; 10(4):325-7. PubMed ID: 1932377
[TBL] [Abstract][Full Text] [Related]
2. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist.
Latini R; Bianchi M; Correale E; Dinarello CA; Fantuzzi G; Fresco C; Maggioni AP; Mengozzi M; Romano S; Shapiro L
J Cardiovasc Pharmacol; 1994 Jan; 23(1):1-6. PubMed ID: 7511719
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
4. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
5. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
6. Proinflammatory cytokines and myocardial viability in patients after acute myocardial infarction.
Kosmala W; Przewlocka-Kosmala M; Mazurek W
Int J Cardiol; 2005 Jun; 101(3):449-56. PubMed ID: 15907414
[TBL] [Abstract][Full Text] [Related]
7. [Platelet activation in the early phases of acute myocardial infarction].
Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
[TBL] [Abstract][Full Text] [Related]
8. Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI; White HD; Modan M; Diaz R; Hampton JR; Heikkila J; Kristinsson A; Moulopoulos S; Paolasso EA; Van der Werf T
Arch Intern Med; 1994 Oct; 154(19):2237-42. PubMed ID: 7944845
[TBL] [Abstract][Full Text] [Related]
9. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
10. The importance of timing of thrombolytic therapy as shown in clinical trials.
Pepine CJ
Clin Cardiol; 1990 Aug; 13(8 Suppl 8):VIII12-7. PubMed ID: 2119925
[TBL] [Abstract][Full Text] [Related]
11. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
Negrini M
G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
[No Abstract] [Full Text] [Related]
12. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
13. Safe use of thrombolysis in the elderly.
Wittry MD; Thornton TA; Chaitman BR
Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296
[TBL] [Abstract][Full Text] [Related]
14. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans.
Chia S; Qadan M; Newton R; Ludlam CA; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):695-701. PubMed ID: 12692009
[TBL] [Abstract][Full Text] [Related]
15. Thrombolytic therapy: a review of the literature on streptokinase and tissue plasminogen activator with implications for practice.
Brewer-Senerchia C
Crit Care Nurs Clin North Am; 1989 Jun; 1(2):359-71. PubMed ID: 2510771
[TBL] [Abstract][Full Text] [Related]
16. Coronary thrombolysis with clot-selective plasminogen activators.
Collen D; Bounameaux H
Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
[TBL] [Abstract][Full Text] [Related]
17. Long term effects of thrombolytic therapy in acute myocardial infarction.
Shah LS
J Assoc Physicians India; 1994 Jan; 42(1):9-11. PubMed ID: 7836276
[No Abstract] [Full Text] [Related]
18. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
Bruna C; Rossetti G; Vado A; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Menardi E; Uslenghi E
G Ital Cardiol; 1998 Jan; 28(1):3-11. PubMed ID: 9493040
[TBL] [Abstract][Full Text] [Related]
19. [Effects of reperfusion and coronary reocclusion on the variability of heart rate in patients with acute myocardial infarction].
Pizzi C; Costa GM; Borghi A; Premuda G; Tondini C; Magri G; Cordioli E; Bugiardini R
Cardiologia; 1999 Feb; 44(2):181-6. PubMed ID: 10208055
[TBL] [Abstract][Full Text] [Related]
20. [Levels of tumor necrosis factor (TNF-alpha) and interleukin 6 (IL-6) in serum of patients with acute myocardial infarction].
Halawa B; Salomon P; Jołda-Mydłowska B; Zyśko D
Pol Arch Med Wewn; 1999 Mar; 101(3):197-203. PubMed ID: 10697395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
